FDA Approves Novel Treatment for Hairy Cell Leukemia
FRIDAY, Sept. 14, 2018 -- Lumoxiti (moxetumomab pasudotox-tdfk) injection has been approved to treat certain instances of relapsed or refractory hairy cell leukemia (HCL), the U.S. Food and Drug Administration said yesterday. Lumoxiti, a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 14, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves Lumoxiti, an Immunotoxin for Hairy Cell Leukemia FDA Approves Lumoxiti, an Immunotoxin for Hairy Cell Leukemia
Moxetumomab pasudotox is a CD22-directed cytotoxin or immunotoxin and is a first-in-class type of treatment for patients with HCLFDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Lumoxiti (moxetumomab pasudotox-tdfk) for Hairy Cell Leukemia
September 13, 2018 -- The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 13, 2018 Category: Drugs & Pharmacology Source Type: news

Lumoxiti OK'd for Hairy Cell Leukemia
(MedPage Today) -- FDA approval marks first anti-CD22 drug for treating the rare disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 13, 2018 Category: Hematology Source Type: news

FDA approves AstraZeneca's drug for rare form of blood cancer
The U.S. Food and Drug Administration said on Thursday it approved AstraZeneca Plc's treatment for hairy cell leukemia, a slow-growing type of blood cancer. (Source: Reuters: Health)
Source: Reuters: Health - September 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves new kind of treatment for hairy cell leukemia
FDA approves Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 13, 2018 Category: American Health Source Type: news

Novel Treatment Approved for'Hairy Cell' Leukemia
THURSDAY, Sept. 13, 2018 -- Lumoxiti injection has been approved to treat certain instances of relapsed or refractory " hairy cell " leukemia (HCL), the U.S. Food and Drug Administration said Thursday. Lumoxiti (moxetumomab pasudotox-tdfk) is among a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 13, 2018 Category: General Medicine Source Type: news

Novel Treatment, Lumoxiti Injection, Approved for'Hairy Cell' Leukemia
THURSDAY, Sept. 13, 2018 -- Lumoxiti injection has been approved to treat certain instances of relapsed or refractory " hairy cell " leukemia (HCL), the U.S. Food and Drug Administration said Thursday. Lumoxiti (moxetumomab pasudotox-tdfk) is among a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 13, 2018 Category: General Medicine Source Type: news

FDA approves new kind of treatment for hairy cell leukemia
The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Lumoxiti is a CD22-directed cytotoxin and is the first of this type of treatment for patients with HCL. (Source: World Pharma News)
Source: World Pharma News - September 13, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

US FDA Accepts Biologics License Application for Moxetumomab Pasudotox in Hairy Cell Leukemia
April 3, 2018 AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for moxetumomab pasudotox, an... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - April 3, 2018 Category: Drugs & Pharmacology Source Type: news

Medical News Today: What is hairy cell leukemia and how is it treated?
This article looks at the symptoms, causes, and treatment options for the disease. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 16, 2018 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Chronic Lymphocytic Leukemia and Hairy Cell Leukemia
This slide show on chronic lymphocytic leukemia (CLL) and hairy cell leukemia includes images of atypical lymphocytes, the disease in bone marrow aspirates, involved in other organs, and more. (Source: CancerNetwork)
Source: CancerNetwork - September 2, 2016 Category: Cancer & Oncology Authors: Cesar A. Moran, MD Source Type: news

Glyphosate: Claims against Monsanto for 'Farmer's Cancer'
Studies of occupational exposure to Glyphosate report increased risks for non-Hodgkin Lymphoma, Multiple Myeloma, Hairy Cell Leukemia, and Chronic Lymphocytic Leukemia (Source: Disabled World)
Source: Disabled World - March 17, 2016 Category: Disability Tags: Warnings - Alerts & Advisories Source Type: news

Zelboraf 'Highly Effective' in Hairy Cell Leukemia (CME/CE)
(MedPage Today) -- Short course of BRAF blockade with vemurafenib proven helpful (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 31, 2015 Category: Hematology Source Type: news

Your NEJM Group Today: Fever, Cough & Rash Case; Safe Use of Direct Oral Anticoagulants; Colorado IM Opportunity (FREE)
By the Editors NEJM Group offers so many valuable resources for practicing clinicians. Here's what we chose for you today:NEJM Clinical Practice Center: Clinical Problem-Solving: A 67-year-old man with hairy-cell leukemia … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 7, 2015 Category: Primary Care Source Type: news

BRAF Inhibitor Is Effective in Hairy Cell LeukemiaBRAF Inhibitor Is Effective in Hairy Cell Leukemia
The drug could be important for the many patients who lose response or relapse with the most effective conventional therapies. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 16, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

20-Year Data on 'Young' Patients With Hairy Cell Leukemia20-Year Data on 'Young' Patients With Hairy Cell Leukemia
The largest ever study on the use of cladribine in patients younger than 40 years at diagnosis comes from the Scripps Clinic. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 22, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Localized renal aspergillosis with hairy cell leukemia: a review of urinary tract aspergillosis in malignant and nonmalignant conditions
Hartman BJ, Coleman M, Brause BD, Saletan S (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - January 17, 2013 Category: Respiratory Medicine Source Type: news